Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates
$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.
$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.